GlassScriptPhysician profile
Ashish Sharma
NPI 1003992736
$3,934.35
in general payments reported to CMS, 2019-2025
22 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $402 · 2021: $809 · 2022: $728 · 2023: $1,167 · 2024: $382 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886 · Travel and Lodging: $791 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.90 |
| Travel and Lodging | $791.40 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,343.72 | 2019-2024 | Linzess, Viberzi, Creon |
| Ovesco Endoscopy USA, INC. | $791.40 | 2023 | |
| Nestle Healthcare Nutrition INC. | $309.21 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $251.21 | 2019-2024 | Entyvio, Gattex |
| Medtronic, INC. | $207.00 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.14 | 2020-2023 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $148.12 | 2025 | Rezdiffra |
| Array Biopharma INC | $136.37 | 2019 | |
| Gilead Sciences, INC. | $114.74 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $104.19 | 2019-2023 | Dificid |
| Janssen Biotech, INC. | $80.76 | 2023-2024 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $43.12 | 2022-2024 | Zeposia |
| Genzyme Corporation | $42.31 | 2024 | |
| Lilly USA, LLC | $25.41 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $24.06 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $20.00 | 2024 | Kcentra |
| Vivus LLC | $17.24 | 2020 | |
| Ironwood Pharmaceuticals, INC | $17.18 | 2022 | |
| Fresenius Kabi USA, LLC | $16.14 | 2023 | Idacio |
| Exact Sciences Corporation | $13.94 | 2023 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $12.94 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.